In NSCLC with ROS1 rearrangement,crizotinib can be used as first-line treatment [5, 6, 7, 8]; however, cardiotoxicitycaused by different anti-cancer drugs has long been recognized [11]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.